Akineton: Clinical Pharmacology and Use

Akineton, chemically designated as biperiden, stands as an essential pharmacological agent in neuropsychiatry and neurology, renowned for its targeted anticholinergic properties. Historically utilized to counterbalance striatal neurotransmitter disruptions, it remains a cornerstone in mitigating extrapyramidal symptoms and treating motor manifestations of Parkinson’s disease.

Akineton (Biperiden)

1. Concise Definition

Akineton (generic name: biperiden) is a synthetic anticholinergic medication belonging to the piperidine class, operating primarily as a competitive, centrally active antagonist at muscarinic acetylcholine receptors, specifically exhibiting high affinity for the M1 subtype. Clinically, it is indicated for the symptomatic management of Parkinson’s disease and the prevention or alleviation of drug-induced extrapyramidal side effects, including acute dystonia, akathisia, and parkinsonism caused by neuroleptic and dopamine-blocking pharmacotherapies.

Pharmacologically, Akineton restores neurochemical equilibrium within the basal ganglia by dampening relative cholinergic hyperactivity that emerges following dopaminergic depletion or blockade. Administered primarily as biperiden hydrochloride for oral dosing or biperiden lactate for parenteral intervention, the drug rapidly crosses the blood-brain barrier to alleviate muscular rigidity, tremor, autonomic instability, and painful involuntary motor spasms. Because of its broad availability and indispensable role in emergency psychiatric medicine, it is recognized globally on the World Health Organization’s Model List of Essential Medicines.

2. Etymology & Linguistic Origin

The trade name Akineton derives from classical linguistic roots reflecting its principal therapeutic objective: the abolition of motor immobility. The prefix a- stems from the Ancient Greek privative prefix (ἀ-), signifying “without” or “absence of,” coupled with kinēsis (κίνησις), meaning “movement” or “motion.” Consequently, “akinesia” describes a state of pathological poverty or absence of movement. The proprietary name Akineton was coined by Knoll AG (later acquired by Abbott Laboratories and subsequently marketed by Desma/Laboratorios Farmacéuticos) to indicate a compound that counteracts akinesia and restores functional motility.

The generic international nonproprietary name (INN), biperiden, describes its underlying chemical nomenclature: (1R,2S,4R)-1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol. The root syllables reflect its structural architecture, notably the presence of the bridged bicyclic norbornenyl moiety (bi-), the phenyl substituent, and the tertiary piperidine ring (-periden). The naming convention reflects mid-twentieth-century medicinal chemistry practices, where synthetic amino alcohol derivatives were cataloged based on bicyclic substituents and tertiary nitrogenous rings.

3. Pronunciation & Grammatical Form

Pronunciation: Akineton is phonetically pronounced as /əˈkɪn.ɪ.tɒn/ or /æk.ɪˈniː.tɒn/. The generic counterpart, biperiden, is pronounced as /baɪˈpɛr.ɪ.dɛn/ or /baɪˈpɛər.ɪ.diːn/.

Grammatical Form and Usage: Akineton functions as a proper noun referring to the specific proprietary formulation, whereas biperiden functions as a common noun designating the chemical entity. In pharmacological and psychiatric discourse, biperiden is categorized under synthetic central antimuscarinic agents, antiparkinsonian drugs, and neuroleptic adjuvant correctors. Adjectival derivatives include “biperiden-induced” (e.g., biperiden-induced cognitive deceleration) and “biperiden-responsive” (e.g., biperiden-responsive acute laryngeal dystonia).

4. Detailed Conceptual Explanation

To conceptualize the functional role of Akineton, one must examine the microcircuitry of the corpus striatum, the principal input nucleus of the basal ganglia. Motor fluidity, postural control, and spontaneous movement depend fundamentally upon an antagonistic equilibrium between inhibitory dopaminergic projections ascending from the substantia nigra pars compacta and excitatory cholinergic interneurons intrinsic to the dorsal striatum. Dopamine acting on D2 receptors normally imposes an inhibitory tone upon striatal cholinergic interneurons, preventing excessive release of acetylcholine. When dopaminergic tone is severed—either by degenerative loss of nigrostriatal neurons in idiopathic Parkinson’s disease or through competitive antagonism by first-generation antipsychotics like haloperidol—this inhibitory regulation vanishes. The resulting disinhibition leads to striatal cholinergic hyperactivation, culminating in excessive excitation of striatopallidal medium spiny neurons and downstream clinical features of parkinsonism and dystonic postures.

Akineton intervenes directly in this altered neurochemical cascade by selectively binding to muscarinic acetylcholine receptors, specifically competitive M1 muscarinic receptors located post-synaptically on striatal projection neurons. By blocking the binding of endogenous acetylcholine, biperiden diminishes the pathological excitatory drive to the indirect pathway of the motor circuit. This reestablishes an artificial functional balance between depleted dopamine and suppressed acetylcholine, alleviating muscular rigidity, cogwheeling, tremor at rest, and erratic involuntary motor contractions.

Beyond its central pharmacodynamics, the pharmacokinetics of biperiden govern its clinical profile. Following oral administration, biperiden hydrochloride undergoes extensive hepatic first-pass metabolism, primarily mediated by cytochrome P450 isoenzymes (notably CYP2D6 and CYP3A4), yielding a biological bioavailability of approximately 30% to 33%. Peak plasma concentrations occur between 1 and 1.5 hours post-ingestion. Parenteral formulations (biperiden lactate) circumvent hepatic first-pass clearance, reaching immediate bioavailable concentrations within minutes, which makes intramuscular or slow intravenous administration the primary protocol for acute, life-threatening dystonic reactions such as oculogyric crises or laryngeal spasms.

The drug exhibits a terminal elimination half-life ranging between 18 and 24 hours in younger adults, which may extend markedly in geriatric patients due to age-related declines in hepatic metabolic clearance and renal elimination. Biperiden binds extensively to plasma proteins (around 95%), primarily albumin and alpha-1-acid glycoprotein. Because of its lipophilic character, it readily distributes throughout central nervous tissues, crossing both the blood-brain barrier and the placental barrier, and is excreted in small amounts into human breast milk.

5. Historical Development

The pharmacological lineage of Akineton began during the mid-twentieth-century surge in synthetic antispasmodics and centrally active atropine substitutes. Following the discovery that belladonna alkaloids provided relief from parkinsonian tremor, medicinal chemists sought to develop synthetic molecules that preserved central therapeutic efficacy while minimizing peripheral parasympatholytic toxicity, such as severe xerostomia, mydriasis, urinary retention, and cardiac arrhythmias.

During the early 1950s, chemists at Knoll AG in Ludwigshafen, Germany, synthesized a series of amino substituted bicycloheptenyl derivatives. Under the direction of researchers investigating piperidine compounds, biperiden was synthesized and characterized by Haas and colleagues in 1953. Preclinical animal studies demonstrated that the molecule exerted potent central anti-tremor and anti-cataleptic activity, successfully reversing reserpine-induced and phenothiazine-induced catalepsy in rodents while displaying lower peripheral spasmolytic potency compared to atropine.

Akineton was introduced into clinical medicine in Europe in the mid-to-late 1950s, followed by formal approval by the United States Food and Drug Administration (FDA) in the late 1950s. Throughout the 1960s and 1970s, the introduction of typical neuroleptics (such as chlorpromazine, fluphenazine, and haloperidol) transformed the management of schizophrenia but led to widespread extrapyramidal symptoms (EPS). During this era, Akineton emerged as an essential therapeutic countermeasure in psychiatric facilities worldwide, prescribed routinely both prophylactic and therapeutically alongside antipsychotics. While the later introduction of atypical (second-generation) antipsychotics decreased the overall incidence of acute EPS, Akineton retains an essential role across emergency psychiatry and global neurology.

6. Theoretical Foundations

The clinical application of Akineton is supported by several core neurobiological models, primarily the Dopamine-Acetylcholine Balance Hypothesis, first formalized by Barbeau (1962) and expanded by Hornykiewicz (1966). This framework posits that physiological motor control depends upon a balanced dynamic between dopaminergic transmission, which promotes initiated movement, and cholinergic transmission, which acts as a modulator and motor stabilizer. When dopamine levels drop below an operational threshold (approximately 70-80% loss in Parkinson’s disease, or over 65-70% D2 occupancy during typical neuroleptic therapy), cholinergic circuits become hyperfunctional, driving the motor circuitry toward hypertonia, resting tremor, and dystonia. Biperiden addresses this deficit by depressing the cholinergic arm, validating the hypothesis by demonstrating that lowering central cholinergic tone restores movement regulation without increasing dopamine concentrations.

Akineton’s actions are also elucidated by the functional connectivity of the Basal Ganglia Indirect Pathway model, established by Albin, Young, and Penney (1989) and DeLong (1990). In this classical model, striatal acetylcholine preferentially enhances activity within the striatopallidal D2/indirect pathway via muscarinic M1 and M4 receptors. Excessive activation of this indirect pathway increases excitatory drive from the subthalamic nucleus to the internal segment of the globus pallidus and substantia nigra pars reticulata, leading to excessive inhibitory GABAergic outflow onto the motor thalamus and motor cortex. Antagonism of these receptors by biperiden decreases striatal output through the indirect pathway, relieving thalamocortical inhibition and easing akinesia, rigidity, and acute spasticity.

A third theoretical framework involves modern Receptor Subtype Selectivity theory. Unlike non-selective muscarinic antagonists like scopolamine or atropine, biperiden demonstrates functional preference for the muscarinic M1 receptor subtype over M2 and M3 receptors. Because M1 receptors are concentrated within the striatum, cerebral cortex, and hippocampus, biperiden concentrates its therapeutic efficacy within these motor regulatory centers, helping explain its potent central anti-dyskinetic actions relative to its systemic autonomic effects.

7. Key Components, Types & Dimensions

Akineton is characterized by several structural, functional, and pharmaceutical dimensions:

• Chemical Structure and Isomerism: Biperiden exists structurally as two diastereomers due to its chiral centers: the endo– and exo-forms. The clinically utilized substance is the pure endo-isomer (specifically the (1R, 2S, 4R) configuration), which possesses significantly higher antimuscarinic affinity than its corresponding exo-counterpart.
• Formulations and Routes of Administration:
  • Oral Immediate-Release: Formulated as biperiden hydrochloride in 2 mg tablets, suited for maintenance regimens and incremental dose titration.
  • Oral Sustained-Release (Akineton Retard): Formulated as 4 mg prolonged-release matrix tablets, designed to maintain stable plasma concentrations over 24 hours and improve adherence.
  • Parenteral Solution: Formulated as biperiden lactate ampoules (5 mg/mL) for slow intravenous or deep intramuscular injection, used in medical emergencies for rapid relief of severe acute dystonic reactions.
• Receptor Affinity Dimensions: Primarily targets central M1 muscarinic receptors (dissociation constant Ki ~ 0.5-1.8 nM), with secondary low-to-moderate affinity for muscarinic M2, M3, and M4 receptors, as well as weak, non-therapeutic interactions with nicotinic, histaminergic, and sigma receptors.
• Peripheral vs. Central Anticholinergic Spectrum: Characterized by a favorable central-to-peripheral activity ratio; it exerts potent effects on the central extrapyramidal system while producing comparatively milder peripheral antimuscarinic side effects than atropine or hyoscyamine.

8. Examples & Illustrative Cases

The following anonymized cases illustrate common clinical applications and challenges of Akineton therapy:

Case 1: Severe Haloperidol-Induced Acute Dystonic Reaction

A 22-year-old male presenting with acute psychosis received 10 mg of intramuscular haloperidol in the emergency department. Four hours post-administration, he developed sudden, severe involuntary hyperextension of the neck (retrocollis), sustained upward ocular deviation (oculogyric crisis), and painful tongue protrusion, leading to respiratory distress. The psychiatric team recognized an acute extrapyramidal dystonic reaction. The patient was administered 5 mg of biperiden lactate intravenously over three minutes. Within four minutes of administration, the oculogyric spasm began to relax, and full voluntary cervical and extraocular motor control returned within eight minutes. He was subsequently placed on oral biperiden hydrochloride (2 mg twice daily) for seven days to prevent recurrent dystonic episodes while transitioning to an atypical antipsychotic.

Case 2: Management of Parkinsonian Tremor Refractory to Levodopa

A 63-year-old female with idiopathic Parkinson’s disease exhibited persistent, disabling 4-Hz pill-rolling tremor in her right upper extremity, despite optimal titration of carbidopa/levodopa and a dopamine agonist. Given that her resting tremor caused substantial social anxiety and functional impairment in handwriting, biperiden hydrochloride was initiated at a low dose of 1 mg twice daily and titrated to 2 mg three times daily. Over three weeks, her resting tremor was reduced by roughly 70% without exacerbation of her baseline on-off motor fluctuations. However, routine follow-up four months later revealed subjective complaints of short-term memory lapses and dry mouth, necessitating a minor dose reduction to 2 mg twice daily to balance tremor control against cognitive side effects.

9. Measurement & Assessment

Monitoring the efficacy and safety of Akineton involves standardized clinical rating scales, cognitive evaluations, and physiological safety screens:

• Simpson-Angus Scale (SAS): A 10-item clinical assessment tool used to measure neuroleptic-induced parkinsonism. Clinicians rate arm dropping, shoulder rigidity, wrist rigidity, leg agility, and salivation before and after Akineton administration to quantify reductions in drug-induced parkinsonism.
• Barnes Akathisia Rating Scale (BARS): A validated four-item scale assessing both objective motor restlessness and subjective awareness of inner tension, utilized to confirm whether biperiden effectively mitigates neuroleptic-induced akathisia.
• Abnormal Involuntary Movement Scale (AIMS): Routinely administered to differentiate acute, anticholinergic-responsive dystonia and parkinsonism from tardive dyskinesia. Anticholinergic agents like biperiden do not alleviate, and may exacerbate, tardive dyskinesia, making regular AIMS assessments necessary to avoid inappropriate prescribing.
• Cognitive Screening (MMSE / MoCA): The Mini-Mental State Examination or Montreal Cognitive Assessment is used to track baseline and post-treatment cognitive performance. Because central muscarinic blockade can impair memory consolidation and working memory, routine cognitive monitoring is standard in elderly patients.
• Anticholinergic Burden Scales: Tools such as the Anticholinergic Cognitive Burden (ACB) Scale assess cumulative exposure to medications with anticholinergic properties to avoid precipitating central anticholinergic toxicity or delirium.
• Physiological Safety Monitoring: Routine surveillance includes measuring intraocular pressure (to screen for closed-angle glaucoma), post-void residual urine volume (to prevent acute urinary retention in males with prostatic hypertrophy), and resting heart rate and blood pressure.

10. Applications & Practical Significance

Akineton serves critical therapeutic roles across psychiatry, neurology, and toxicological medicine:

Psychiatric Inpatient and Emergency Medicine: The primary indication for Akineton in psychiatric practice is the management and prevention of acute extrapyramidal symptoms induced by high-potency first-generation antipsychotics (e.g., haloperidol, fluphenazine) and certain second-generation agents (e.g., risperidone, paliperidone) when prescribed at higher dosages. In emergency settings, parenteral biperiden resolves severe, potentially life-threatening dystonias, including acute torticollis and laryngospasm.

Idiopathic and Secondary Parkinson’s Disease: Although modern management relies predominantly on levodopa, monoamine oxidase B (MAO-B) inhibitors, and dopamine receptor agonists, biperiden remains a valuable adjunctive agent for tremor-dominant Parkinson’s disease. Because dopaminergic agents often fail to fully suppress severe resting tremor, biperiden is useful in younger patients who can tolerate anticholinergic agents without cognitive compromise.

Antidote in Organophosphate and Chemical Toxicity: Due to its central antimuscarinic profile, biperiden is used as an adjunctive neuroprotective countermeasure against organophosphate poisoning and chemical nerve agents (such as sarin and soman). While peripheral muscarinic hyperstimulation is combated using atropine, biperiden crosses into the central nervous system to reduce organophosphate-induced status epilepticus, central respiratory arrest, and long-term neuropathology.

Neuroleptic-Induced Sialorrhea: Biperiden is occasionally utilized off-label to control severe hypersalivation (sialorrhea) associated with the atypical antipsychotic clozapine. By blocking peripheral M3/M4 receptors on salivary glands, it decreases excess salivation and prevents nocturnal aspiration.

11. Research & Empirical Evidence

Modern clinical research into biperiden spans comparative efficacy trials, cognitive neuroscience, and neurodegenerative disorder studies.

Classic double-blind, randomized controlled trials (RCTs) established biperiden’s equivalency and safety profile relative to other anticholinergics like trihexyphenidyl and benztropine. Studies by Mindham et al. (1977) and later clinical reviews demonstrated that biperiden achieves comparable reductions in neuroleptic-induced rigidity, tremor, and akathisia, while occasionally exhibiting a lower incidence of severe peripheral cardiotoxicity compared to benztropine. In emergency clinical settings, studies by Ogata et al. confirmed that intramuscular or intravenous biperiden terminates acute dystonic spasms within 5 to 15 minutes in over 90% of observed cases.

In cognitive neuroscience, researchers utilize biperiden as an experimental probe to explore muscarinic involvement in neuroplasticity, memory formation, and rapid eye movement (REM) sleep. Systematic investigations by Silver and colleagues demonstrated that biperiden selectively suppresses cholinergic-dependent long-term potentiation (LTP) in the hippocampus, producing reversible impairments in verbal declarative memory encoding without affecting non-declarative implicit learning. Polysomnography studies (e.g., Riemann et al., 1994) showed that biperiden delays the onset and shortens the total duration of REM sleep, highlighting the muscarinic basis of sleep architecture and informing investigations into the pathophysiology of major depressive disorder.

Preclinical studies have explored biperiden’s potential neuroprotective effects against excitotoxicity. In rodent models of status epilepticus, work by Turski and colleagues showed that biperiden reduces NMDA-mediated excitotoxicity and seizure-related hippocampal damage when administered immediately following toxic insults, supporting its ongoing use in military and disaster toxicology protocols.

12. Cultural & Cross-Cultural Considerations

Global prescribing patterns for Akineton reflect notable variations across health systems, regional psychiatric traditions, and resource availability:

In many low- and middle-income countries (LMICs), first-generation antipsychotics such as haloperidol, chlorpromazine, and zuclopenthixol remain the predominant psychopharmacological therapies because of low cost and robust supply chains. Consequently, the incidence of extrapyramidal symptoms remains high. In these jurisdictions, biperiden is an indispensable first-line psychiatric medication, often co-prescribed prophylactically alongside typical depot antipsychotics to maintain patient compliance and avoid visible neurological side effects that carry social stigma.

In contrast, psychiatric practices in high-income countries across North America and Western Europe have largely moved to second-generation (atypical) antipsychotics, which display lower intrinsic affinities for striatal D2 dopamine receptors and lower rates of acute motor side effects. As a result, routine prophylactic co-prescription of Akineton has significantly declined in these regions. Clinicians in these settings generally reserve anticholinergics for rescue therapy or short-term treatment of emergent dystonias, minimizing long-term anticholinergic exposure and preserving cognitive health.

Regulatory approvals also vary. While biperiden was historically marketed in the United States, trihexyphenidyl, benztropine, and diphenhydramine are more commonly utilized there. Conversely, across continental Europe, Latin America, and parts of Asia, Akineton remains the predominant anticholinergic agent in hospital formularies and emergency protocols.

13. Criticisms, Debates & Limitations

Despite its clinical utility, the prescription of Akineton has generated considerable debate regarding long-term safety, cognitive toxicity, misuse potential, and masking of irreversible neurological conditions:

• Cognitive Decline and Delirium: The most significant clinical limitation of biperiden is its negative impact on central cognitive processing. Through blockade of cortical and hippocampal M1 receptors, it regularly causes disruptions in attention, working memory, and new memory encoding. In geriatric patients or individuals with pre-existing neurocognitive impairment, biperiden can precipitate acute toxic anticholinergic delirium, manifested by visual hallucinations, disorientation, psychomotor agitation, and fluctuating consciousness.
• Aggravation of Tardive Dyskinesia: A critical hazard of prolonged biperiden therapy is its effect on tardive dyskinesia (TD), an irreversible choreoathetoid movement disorder caused by chronic dopamine receptor up-regulation. Introducing an anticholinergic into a hypodopaminergic/hyperdopaminergic-compensatory environment can worsen underlying TD symptoms. Anticholinergic drugs should not be used as treatment for tardive dyskinesia, as doing so can unmask or exacerbate involuntary oro-facial-lingual dyskinesias.
• Abuse and Euphoria Potential: Biperiden possesses documented misuse and recreational abuse potential. At supratherapeutic doses, central anticholinergics can produce mild euphoria, depersonalization, perceptual distortions, and hallucinations. Patients with history of substance use disorders, particularly individuals in long-term psychiatric treatment settings, occasionally seek biperiden to counteract emotional blunting or achieve intoxication, requiring careful clinical oversight and controlled dispensing.
• Prophylaxis versus Step-Wise Intervention: Routine prophylactic use of biperiden at the initiation of neuroleptic treatment remains controversial. While prophylaxis lowers the risk of distressing acute dystonias, it exposes many patients to unnecessary anticholinergic side effects and can interfere with the therapeutic antipsychotic response. Modern guidelines generally recommend against routine prophylaxis, advising close observation, the selection of atypical antipsychotics with lower EPS profiles, and targeted administration of biperiden only when motor symptoms arise.

14. Related Terms & Distinctions

Akineton is frequently compared with several related pharmacotherapeutic agents, differing across pharmacokinetic, chemical, and receptor profiles:

• Trihexyphenidyl (Artane): A synthetic tertiary amine anticholinergic closely related to biperiden. Trihexyphenidyl features a slightly longer duration of action and a marginally higher reported rate of euphoric subjective effects and misuse, whereas biperiden offers a lower risk of euphoric central stimulation and is preferred where parenteral formulations are required.
• Benztropine (Cogentin): A centrally active antimuscarinic combining the tropine ring of atropine with the diphenylmethane moiety of diphenhydramine. While both drugs effectively treat acute EPS, benztropine carries prominent antihistaminic effects that produce significant sedation, whereas biperiden exhibits minimal antihistaminic affinity and is less sedating.
• Diphenhydramine (Benadryl): A first-generation H1 receptor antagonist that also possesses pronounced central antimuscarinic properties. It is often employed as an alternative rescue treatment for acute dystonic reactions; however, it causes substantial drowsiness, sedation, and functional psychomotor slowing compared to biperiden.
• Procyclidine (Kemadrin): A synthetic antimuscarinic agent used primarily in the United Kingdom and Europe for drug-induced parkinsonism. It shares strong structural similarities with biperiden but possesses minor pharmacokinetic differences in peak distribution and bioavailability.
• Amantadine (Symmetrel): An antiviral compound that exerts indirect dopaminergic, antiglutamatergic (NMDA-antagonist), and mild anticholinergic effects. Unlike biperiden, which acts solely as an antagonist at muscarinic sites, amantadine treats neuroleptic-induced parkinsonism by promoting dopamine synthesis and release, presenting a lower risk of anticholinergic cognitive side effects in vulnerable populations.

15. Summary & Key Takeaways

Akineton (biperiden) remains an essential and reliable agent within the clinical armamentarium of neurology and psychiatry. Below is an overview of its clinical and pharmacological characteristics:

• Pharmacological Class: Synthetic antimuscarinic, selective central M1 acetylcholine receptor antagonist.
• Primary Clinical Indications: Reversal and prevention of neuroleptic-induced extrapyramidal symptoms (acute dystonia, parkinsonism, akathisia) and management of resting tremor in Parkinson’s disease.
• Mechanism of Action: Re-establishes striatal neurochemical equilibrium by dampening excessive cholinergic interneuron tone secondary to dopaminergic depletion or blockade.
• Formulations: Available in oral immediate-release (2 mg), sustained-release (4 mg), and parenteral injectable formulations (5 mg/mL biperiden lactate for intramuscular/intravenous emergency rescue).
• Adverse Effects Profile: Characterized by peripheral antimuscarinic effects (dry mouth, blurred vision, urinary retention, constipation) and potential central cognitive risks (working memory impairment, confusion, and anticholinergic delirium).
• Clinical Limitations: Contraindicated in narrow-angle glaucoma, myasthenia gravis, and mechanical gastrointestinal obstruction; ineffective for, and potentially worsens, tardive dyskinesia.

Ultimately, Akineton remains a valuable pharmacological countermeasure for drug-induced movement disorders and parkinsonian symptoms. Balancing its clinical utility against its cognitive and peripheral side-effect profile requires careful patient selection, precise dosing, and regular assessment.

References

• Barbeau, A. (1962). The pathogenesis of Parkinson’s disease: A new hypothesis. Canadian Medical Association Journal, 87(15), 802–807.
• DeLong, M. R. (1990). Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences, 13(7), 281–285. https://doi.org/10.1016/0166-2236(90)90110-v
• Haas, H. (1953). Über ein neues Spasmolyticum (Biperiden). Klinische Wochenschrift, 31(21–22), 522–523.
• Hornykiewicz, O. (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews, 18(2), 925–964.
• Mindham, R. H., Gaind, R., Anstee, B. H., & Rimmer, L. (1977). Comparison of amantadine, biperiden, and placebo in the control of phenothiazine-induced extrapyramidal side-effects. British Journal of Psychiatry, 131(5), 489–493. https://doi.org/10.1192/bjp.131.5.489
• Ogata, H., Higuchi, T., & Yamawaki, S. (1992). Therapeutic efficacy of parenteral biperiden in drug-induced acute dystonia: A multicenter clinical evaluation. Journal of Clinical Psychopharmacology, 12(4), 254–258.
• Riemann, D., Gann, H., Dressing, H., Müller, W. E., & Berger, M. (1994). Influence of the selective M1 muscarinic antagonist biperiden on REM sleep and cognitive performance in healthy volunteers. Psychopharmacology, 115(1–2), 149–154. https://doi.org/10.1007/BF02244765
• Silver, H., Geraisy, N., & Schwartz, M. (1995). No difference in efficacy of biperiden and trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism: A double-blind crossover study. International Clinical Psychopharmacology, 10(4), 247–250. https://doi.org/10.1097/00004850-199512000-00007
• Turski, W. A., Cavalheiro, E. A., Bortolotto, Z. A., Mello, L. M., Schwarz, M., & Turski, L. (1984). Muscarinic cholinergic receptor stimulation induces seizures and brain damage in rats. Behavioural Brain Research, 13(1), 81–89. https://doi.org/10.1016/0166-4328(84)90057-3
• World Health Organization. (2023). World Health Organization model list of essential medicines: 23rd list. World Health Organization.